All Stories

  1. Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival

    Article • British Journal of Pharmacology, April 2026, Springer Science + Business Media

    Radwan Massoud

  2. Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis

    Article • Transplantation and Cellular Therapy, April 2026, Elsevier

    Radwan Massoud

  3. <i>Erratum</i> to: “Lower incidence of chronic graft-<i>versus</i>-host disease after ruxolitinib plus extracorporeal photopheresis <i>versus</i> ruxolitinib alone in steroid-refractory acute graft-<i>versus<...

    Article • Haematologica, March 2026, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  4. Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome

    Article • Transplantation and Cellular Therapy, February 2026, Elsevier

    Radwan Massoud

  5. Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation

    Article • British Journal of Pharmacology, January 2026, Springer Science + Business Media

    Radwan Massoud

  6. Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)

    Article • British Journal of Pharmacology, December 2025, Springer Science + Business Media

    Radwan Massoud

  7. Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation

    Article • Biomarker Research, December 2025, Springer Science + Business Media

    Radwan Massoud

  8. Matched unrelated vs. Haploidentical  donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

    Article • Blood, November 2025, American Society of Hematology

    Radwan Massoud

  9. Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT

    Article • British Journal of Pharmacology, October 2025, Springer Science + Business Media

    Radwan Massoud

  10. Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm

    Article • British Journal of Haematology, June 2025, Wiley

    Radwan Massoud

  11. Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation

    Article • Haematologica, March 2025, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  12. Clearance of Driver Mutations after Transplantation for Myelofibrosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2025, New England Journal of Medicine (NEJM/MMS)

    Radwan Massoud

  13. Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients

    Article • Transplantation and Cellular Therapy, January 2025, Elsevier

    Radwan Massoud

  14. Clinical and Immune Effects of Peri‐Transplantation JAK Inhibition for Myelofibrosis

    Article • American Journal of Hematology, November 2024, Wiley

    Radwan Massoud

  15. Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

    Article • Blood, November 2024, American Society of Hematology

    Radwan Massoud

  16. Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

    Article • Blood, November 2024, American Society of Hematology

    Radwan Massoud

  17. Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

    Article • Blood, November 2024, American Society of Hematology

    Radwan Massoud

  18. The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

    Article • Blood, November 2024, American Society of Hematology

    Radwan Massoud

  19. Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post‐Transplant Cyclophosphamide in MRD‐Negative but Not in MRD‐Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Compl...

    Article • European Journal Of Haematology, September 2024, Wiley

    Radwan Massoud

  20. Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation

    Article • British Journal of Pharmacology, June 2024, Springer Science + Business Media

    Radwan Massoud

  21. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

    Article • British Journal of Pharmacology, February 2024, Springer Science + Business Media

    Radwan Massoud

  22. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation

    Article • Cancers, January 2024, MDPI AG

    Radwan Massoud

  23. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR

    Article • Leukemia, January 2024, Springer Science + Business Media

    Radwan Massoud

  24. Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

    Article • Blood, November 2023, American Society of Hematology

    Radwan Massoud

  25. Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

    Article • Blood, November 2023, American Society of Hematology

    Radwan Massoud

  26. Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

    Article • Blood, November 2023, American Society of Hematology

    Radwan Massoud

  27. The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

    Article • Blood, November 2023, American Society of Hematology

    Radwan Massoud

  28. Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas

    Article • European Journal Of Haematology, October 2023, Wiley

    Radwan Massoud

  29. Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon

    Article • Frontiers in Transplantation, June 2023, Frontiers

    Radwan Massoud

  30. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis

    Article • British Journal of Pharmacology, March 2023, Springer Science + Business Media

    Radwan Massoud

  31. Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk undergoing allogeneic stem cell transplantation in CR...

    Article • European Journal Of Haematology, December 2022, Wiley

    Radwan Massoud

  32. Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

    Article • Blood, November 2022, American Society of Hematology

    Radwan Massoud

  33. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

    Article • British Journal of Pharmacology, July 2022, Springer Science + Business Media

    Radwan Massoud

  34. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete R...

    Article • Transplantation and Cellular Therapy, July 2022, Elsevier

    Radwan Massoud

  35. Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia

    Article • Transplantation and Cellular Therapy, May 2022, Elsevier

    Radwan Massoud

  36. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

    Article • Haematologica, December 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  37. Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

    Article • Blood, November 2021, American Society of Hematology

    Radwan Massoud

  38. Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

    Article • Blood, November 2021, American Society of Hematology

    Radwan Massoud

  39. Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia

    Article • Transplantation and Cellular Therapy, October 2021, Elsevier

    Radwan Massoud

  40. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients

    Article • Leukemia Research, June 2021, Elsevier

    Radwan Massoud

  41. A Pin1/PML/P53 axis activated by retinoic acid in <i>NPM-1c</i> acute myeloid leukemia

    Article • Haematologica, May 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  42. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation

    Article • Haematologica, April 2021, Ferrata Storti Foundation (Haematologica)

    Radwan Massoud

  43. Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

    Article • British Journal of Pharmacology, February 2021, Springer Science + Business Media

    Radwan Massoud

  44. Antibody Response to COVID-19 Vaccination in Adults with Haematological Malignancies: A Systematic Review and Meta-Analysis

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Radwan Massoud

  45. Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2020, Elsevier

    Radwan Massoud

  46. The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study

    Article • Current Research in Translational Medicine, April 2020, Elsevier

    Radwan Massoud

  47. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma

    Article • Leukemia & Lymphoma, February 2020, Taylor & Francis

    Radwan Massoud

  48. Assessment of Caries Index and Fluoride Intake in a Pediatric Middle Eastern Population

    Article • The Journal of Contemporary Dental Practice, January 2020, Jaypee Brothers Medical Publishing

    Radwan Massoud

  49. Risk Adapted Therapeutic Strategy of Acute Myeloid Leukemia

    Article • Blood, November 2019, American Society of Hematology

    Radwan Massoud

  50. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2019, Elsevier

    Radwan Massoud

  51. Acute Myeloid Leukemia in the Real-World: Therapeutic Strategy and Outcome in a Single Center

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2019, Elsevier

    Radwan Massoud

  52. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2019, Elsevier

    Radwan Massoud

  53. Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness

    Article • Nature Communications, June 2019, Springer Science + Business Media

    Radwan Massoud

  54. Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia

    Article • Hematology/Oncology and Stem Cell Therapy, December 2018, Elsevier

    Radwan Massoud, Souha Kanj

  55. Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

    Article • Blood, November 2018, American Society of Hematology

    Radwan Massoud

  56. Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation

    Article • British Journal of Pharmacology, October 2018, Springer Science + Business Media

    Radwan Massoud, Souha Kanj

  57. Site specific diagnostic yield of endoscopic biopsies in Gastrointestinal Graft-versus-Host Disease: A tertiary care Center experience

    Article • Current Research in Translational Medicine, September 2018, Elsevier

    Radwan Massoud

  58. Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patient Aged over 76 Years with Refractory Acute Myeloid Leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2018, Elsevier

    Radwan Massoud

  59. Management of Biochemical Relapse during Lenalidomide Maintenance Therapy Post ASCT in Multiple Myeloma: A Descriptive Observational Study of a Single Institution

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2018, Elsevier

    Radwan Massoud

  60. Real Life Experience with Plerixafor and Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Stem Cell Transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2018, Elsevier

    Radwan Massoud

  61. The Efficacy and Safety of Busulfan Dose Intensity with Fludarabine Conditioning Regimen for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. A Single Center Experience

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2018, Elsevier

    Radwan Massoud

  62. Travelling Related Risks After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Referred from Countries with Destroyed Healthcare System to Transplant Center in Adjacent Country; A Single Center Survey

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2018, Elsevier

    Radwan Massoud

  63. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

    Article • August 2018, Elsevier

    Radwan Massoud, Souha Kanj

  64. Thiotepa 10 mg/kg seems superior to Thiotepa 5 mg/kg in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2018, Elsevier

    Radwan Massoud

  65. Progressive multifocal leukoencephalopathy in patients receiving rituximab and cyclophosphamide after haplo-identical T-cell replete transplantation and review of the literature

    Article • Current Research in Translational Medicine, November 2017, Elsevier

    Radwan Massoud, Souha Kanj

  66. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation

    Article • Journal of Clinical Virology, October 2017, Elsevier

    Radwan Massoud, Souha Kanj

  67. Post-Induction Evaluation of Acute Myeloid Leukemia Patients: The Significance of Disease Status at Day 21

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2017, Elsevier

    Radwan Massoud

  68. Sequential Regimen with Thiotepa, Cyclophosphamide, Etoposide, Fludarabine and Busulfan in Allogeneic Stem Cell Transplantation for the Treatment of Relapsed and Refractory Hematological Malignancies

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2017, Elsevier

    Radwan Massoud

  69. Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant

    Article • British Journal of Pharmacology, June 2017, Nature

    Radwan Massoud

  70. Trends in hematopoietic stem cell transplant activity in Lebanon

    Article • Hematology/Oncology and Stem Cell Therapy, June 2017, Elsevier

    Radwan Massoud

  71. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma

    Article • British Journal of Pharmacology, April 2017, Nature

    Radwan Massoud

  72. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

    Article • Cancer, April 2017, Wiley

    Radwan Massoud

  73. Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT

    Article • British Journal of Pharmacology, April 2017, Nature

    Radwan Massoud

  74. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation

    Article • Leukemia & Lymphoma, March 2017, Taylor & Francis

    Radwan Massoud

  75. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis

    Article • Clinical Lymphoma Myeloma & Leukemia, March 2017, Elsevier

    Radwan Massoud

  76. Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  77. Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  78. Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  79. Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  80. Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC)

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  81. Post Transplant Brentuximab Maintenance Appears More Effective Than Post Transplant Salvage Brentuximab for Relapsed/Refractory Hogkin's Lymphoma

    Article • Blood, December 2016, American Society of Hematology

    Radwan Massoud

  82. Post Transplant Brentuximab Maintenance Appears more Effective than Post Transplant Salvage Brentuximab for Relapsed /Refractory Hodgkin Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud

  83. Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud

  84. Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC)

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2016, Elsevier

    Radwan Massoud